SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Concord Biotech - Quaterly Results

08 Nov 2023 Evaluate
A decent increase of about 65.10% in the turnover to Rs. 2623.46 millions was observed for the quarter ended September 2023. The turnover stood at Rs. 1588.99 millions during the similar quarter previous year.The Net Profit of the company reported a remarkable increase of 276.45% to Rs. 844.94  millions  from Rs. 224.45 millions in previous same quarter.Operating profit surged to 1273.15 millions from the corresponding previous quarter of 439.48 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202309 202209 % Var
Sales 2623.46 1588.99 65.10 2623.46 1588.99 65.10 2623.46 1588.99 65.10
Other Income 81.26 60.29 34.78 81.26 60.29 34.78 81.26 60.29 34.78
PBIDT 1273.15 439.48 189.69 1273.15 439.48 189.69 1273.15 439.48 189.69
Interest 8.41 11.10 -24.23 8.41 11.10 -24.23 8.41 11.10 -24.23
PBDT 1264.74 428.38 195.24 1264.74 428.38 195.24 1264.74 428.38 195.24
Depreciation 132.95 125.11 6.27 132.95 125.11 6.27 132.95 125.11 6.27
PBT 1131.79 303.27 273.20 1131.79 303.27 273.20 1131.79 303.27 273.20
TAX 286.85 78.82 263.93 286.85 78.82 263.93 286.85 78.82 263.93
Deferred Tax 9.29 2.24 314.73 9.29 2.24 314.73 9.29 2.24 314.73
PAT 844.94 224.45 276.45 844.94 224.45 276.45 844.94 224.45 276.45
Equity 104.62 104.62 0.00 104.62 104.62 0.00 104.62 104.62 0.00
PBIDTM(%) 48.53 27.66 75.46 48.53 27.66 75.46 48.53 27.66 75.46

Concord Biotech Share Price

1067.40 -13.85 (-1.28%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×